Summary

Selank is a synthetic heptapeptide derived from tuftsin, developed at the Institute of Molecular Genetics in Moscow. It has been studied for anxiolytic (anti-anxiety) and cognitive-enhancing effects, with a body of research primarily from Russian institutions. Evidence is predominantly from animal models and small Russian clinical studies, with limited independent international replication.

Mechanism

Selank is a synthetic tuftsin analogue that modulates immune function (cytokine production), may upregulate BDNF expression in the hippocampus, inhibits enkephalin-degrading enzymes, and influences serotonin and dopamine metabolism. These combined effects are thought to underlie its anxiolytic and cognitive-enhancing properties without the sedation associated with benzodiazepines.

Evidence base

Evidence is predominantly from Russian institutions. Animal studies show anxiolytic and cognitive effects comparable to benzodiazepines without sedation. Small Russian clinical studies report anxiety reduction in generalised anxiety disorder and improvements in post-viral fatigue. No large-scale international RCTs have been published. Evidence quality is limited by small samples, single-group origin, and lack of independent replication.

Protocols

Commonly discussed in research contexts: intranasal 150–300 mcg, 1–3 times daily; subcutaneous 250–500 mcg. Cycles of 10–14 days. Based on Russian clinical literature and community discussion, not large-scale trials.

Not controlled under the Misuse of Drugs Act 1971. Not a POM. Not licensed as a medicine in the UK (registered in Russia, but this has no UK standing). Legal to purchase and possess for research purposes; not approved for human consumption.

Vendor notes

Selank is available from some UK research peptide vendors, typically in lyophilised form or as intranasal solutions. No vendors have been independently verified by Peptide Data at this time.

References

  1. Kozlovskaya, M.M. et al. (2003). Selank: Anxiolytic and immunomodulatory effects. Bulletin of Experimental Biology and Medicine, 135(4), 371–374.
  2. Inozemtseva, L.S. et al. (2008). Effect of Selank on BDNF expression in the rat brain. Bulletin of Experimental Biology and Medicine, 145(2), 170–173.
  3. Zozulya, A.A. et al. (2001). Selank: An anxiolytic peptide without sedative effects. Russian Physiological Journal, 87(5), 624–631.
  4. Seredenin, S.B. et al. (2010). Selank: Pharmacological effects and mechanisms of action. Eksperimental'naya i Klinicheskaya Farmakologiya, 73(4), 38–43.
  5. Umarova, B.A. et al. (2017). Selank in the treatment of post-influenza asthenic syndrome. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova, 117(2), 48–53.